UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 15, 2014
ANTARES PHARMA, INC.
(Exact name of registrant specified in its charter)
|
|
|
|
|
Delaware |
|
1-32302 |
|
41-1350192 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
|
|
|
100 Princeton South, Suite 300, Ewing, NJ |
|
08628 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone, including area code: (609) 359-3020
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any
of the following provisions (see General Instruction A.2. below):
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02. |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
(c) Effective September 15, 2014, Mr. Robert F. Apple was promoted to the position of Executive Vice President and Chief Operating Officer of
Antares Pharma, Inc. Mr. Apple joined the Company in February 2006 as Senior Vice President and Chief Financial Officer and was promoted to Executive Vice President, Chief Financial Officer and President of the Parenteral Products Group in
2008. Prior to joining the Company, Mr. Apple served as Chief Operating and Financial Officer at InKine Pharmaceutical Company, Inc. from 2003 to 2005, and Chief Financial Officer from 1997 to 2002. In his role as Chief Operating Officer,
Mr. Apple will be responsible for all aspects of operations at Antares Pharma including sales, marketing, manufacturing and product development. In connection with his promotion, Mr. Apple will receive a 10% increase to his current base
salary.
Item 7.01 |
Regulation FD Disclosure. |
On September 15, 2014, Antares Pharma, Inc. issued a press release
announcing that Robert F. Apple has been promoted to Chief Operating Officer effective immediately. The Company also announced that a retained search has begun to fill the position of Chief Financial Officer. Until the position is filled,
Mr. Apple will continue to serve as the Companys Chief Financial Officer as he has since he joined Antares Pharma in 2006.
The full text of
such press release is included as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits.
|
|
|
Exhibit No. |
|
Description |
|
|
99.1 |
|
Press Release, dated September 15, 2014, issued by Antares Pharma, Inc. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ANTARES PHARMA, INC. |
|
|
|
|
|
Date: |
|
September 15, 2014 |
|
|
|
By: |
|
/s/ Jennifer Evans Stacey |
|
|
|
|
|
|
Name: |
|
Jennifer Evans Stacey |
|
|
|
|
|
|
Title: |
|
Senior Vice President, General Counsel,
Human Resources & Secretary |
EXHIBIT INDEX
Exhibit
|
|
|
Exhibit No. |
|
Description |
|
|
99.1 |
|
Press Release, dated September 15, 2014, issued by Antares Pharma, Inc. |
Exhibit 99.1
ANTARES PHARMA ANNOUNCES PROMOTION OF ROBERT F. APPLE
TO CHIEF OPERATING OFFICER
EWING, NJ,
September 15, 2014 Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple has been promoted to Chief Operating Officer effective immediately. The Company also announced that a retained search has begun to fill the
position of Chief Financial Officer. Until the position is filled, Mr. Apple will continue to serve as the Companys Chief Financial Officer as he has since he joined Antares Pharma in 2006.
Eamonn P. Hobbs, President and Chief Executive Officer of the Company, stated, Bobs responsibilities have expanded since he joined the Company to
include oversight of the Parenteral Products Group, and we believe that elevating him to Chief Operating Officer will leverage his prior commercial background and his technical expertise in the combination drug/device area, helping the Company
increase overall efficiency. Mr. Hobbs continued, We congratulate Bob on his promotion and look forward his contributions to Antares Pharmas future strategic growth.
Mr. Apple joined the Company in February 2006 as Senior Vice President and Chief Financial Officer and was promoted to Executive Vice President, Chief
Financial Officer and President of the Parenteral Products Group in 2008. Prior to joining the Company, Mr. Apple served as Chief Operating and Financial Officer at InKine Pharmaceutical Company, Inc. (InKine) from 2003 to 2005, and
Chief Financial Officer from 1997 to 2002. In his role as Chief Operating Officer, Mr. Apple was responsible for building a 60 person in-house sales team and grew product sales until the ultimate acquisition of InKine by Salix Pharmaceuticals,
Inc. In his role as Chief Operating Officer, Mr. Apple will be responsible for all aspects of operations at Antares Pharma including sales, marketing, manufacturing and product development.
Im excited to assume the newly created role of Chief Operating Officer, stated Robert F. Apple. Antares Pharma has grown from an
innovator of novel technologies to a combination drug/device commercial company in the eight plus years Ive been here. I believe that the combination of my commercial, technical and financial backgrounds will provide a great source of
experience as we move Antares toward becoming a fully integrated pharmaceutical company.
About Antares Pharma
Antares Pharma focuses on self-administered parenteral pharmaceutical products. The Company markets OTREXUP (methotrexate) injection for the treatment of
adults with severe active rheumatoid arthritis and children with active polyarticular juvenile idiopathic arthritis. LEO Pharma markets OTREXUP to dermatologists for adults with severe recalcitrant psoriasis. Antares Pharma is also developing
VIBEX® QS T for testosterone replacement therapy. The Companys technology platforms include VIBEX® disposable Medi-Jet,
disposable multi-use pen injectors and reusable needle-free injectors marketed as Tjet® and Zomajet® by Teva Pharmaceutical Industries,
Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin® [somatropin (rDNA origin) for injection] human
growth hormone (hGH), VIBEX® epinephrine and several other products. In the U.S. Antares has received FDA approval for Gelnique 3% (oxybutynin) gel, a treatment for overactive bladder
that is marketed by Actavis. Elestrin® (estradiol gel) is FDA approved for the treatment of moderate-to-severe vasomotor symptoms associated with
menopause, and is marketed in the U.S. by Meda Pharma.
1 of 2
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of
1995, including statements made with respect to the contributions of Mr. Robert F. Apple to Antares Pharma in the role of Chief Operating Officer and impact thereof, and products in development; and other statements regarding matters that
are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future
results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as may, will,
should, would, expect, intend, plan, anticipate, believe,
estimate, predict, potential, seem, seek, future, continue, or
appear or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Such forward-looking statements are not guarantees of future performance and are
subject to risks and uncertainties that may cause actual results to differ materially from those anticipated by the forward-looking statements. Additional information concerning these and other factors that may cause actual results to differ
materially from those anticipated in the forward-looking statements is contained in the Risk Factors section of the Companys Annual Report on Form 10-K for the year ended December 31, 2013, and in the Companys other
periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on
information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as
required by law.
Investor Contacts:
Jack
Howarth
Vice President, Corporate Affairs
(609) 359-3016
jhowarth@antarespharma.com
2 of 2
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jul 2023 to Jul 2024